Evidence map›Paper›PMID 40683209›Full record

ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2025

Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds.

Yan Zhu, Laxmi Moksha, Rebecca Salowe, Vrathasha Vrathasha, Kenneth Pham, Marine-Ayan Ibrahim Aibo, Roy Lee, Mina Halimitabrizi, Isabel Di Rosa, Joan M O'Brien

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yan ZhuCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: yan.zhu1@pennmedicine.upenn.edu.
Laxmi MokshaCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: moksha.laxmi@pennmedicine.upenn.edu.
Rebecca SaloweCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: rebecca.salowe@pennmedicine.upenn.edu.
Vrathasha VrathashaCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: vrathasha.vrathasha@pennmedicine.upenn.edu.
Kenneth PhamCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: kenneth.pham@pennmedicine.upenn.edu.
Marine-Ayan Ibrahim AiboCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: marine-ayan.ibrahimaibo@pennmedicine.upenn.edu.
Roy LeeCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: roylee@pennmedicine.upenn.edu.
Mina HalimitabriziCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: mina.halimitabrizi@pennmedicine.upenn.edu.
Isabel Di RosaCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: isabel.dirosa@pennmedicine.upenn.edu.
Joan M O'BrienCenter for Genetics of Complex Disease, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: joan.o'brien@pennmedicine.upenn.edu.

Funding

P30-CORE GRANT FOR VISION RESEARCHP30EY001583 · UNIVERSITY OF PENNSYLVANIA · 1985 to 2025
$4.4M
Primary Open Angle African-American Glaucoma Genetics Study RenewalR01EY023557 · UNIVERSITY OF PENNSYLVANIA · 2025 to 2025
$1.4M
NEI NIH HHS P30 EY001583NEI NIH HHS R01 EY023557
6 · The paper itself

Abstract

Glaucoma is a group of progressive optic neuropathies characterized by the degeneration of retinal ganglion cells (RGCs) and their axons, leading to irreversible vision loss or blindness if left untreated. Current glaucoma treatments primarily focus on lowering intraocular pressure (IOP), the only proven method to slow disease progression. However, these treatments do not effectively address RGC loss or promote optic nerve regeneration. Emerging research into both natural and synthetic bioactive compounds offers promising new avenues for glaucoma management. This review explores the multifaceted therapeutic potential of bioactive compounds in glaucoma treatment, focusing on their mechanisms of action in IOP reduction and neuroprotection, as well as antioxidant and anti-inflammatory effects. We further review ongoing clinical trials and discuss significant challenges to clinical translation, including the issues of bioavailability, standardization, long-term safety, and regulatory challenges. Furthermore, this paper highlights the potential of integrating precision medicine into bioactive treatments, emphasizing the value of personalized care based on genetic and phenotypic profiles. Finally, the review discusses the role of combination therapies, which leverage the complementary mechanisms of bioactive compounds and conventional treatments. As research progresses, the development of targeted, bioactive-based therapies could transform glaucoma management, offering more comprehensive and effective options for patients with this vision-threatening disease.

Indexed as

AntioxidantsGlaucomaNeuroprotectionNeuroprotective AgentsPrecision MedicineAnimalsHumansIntraocular PressureRetinal Ganglion CellsAntioxidantsNeuroprotective AgentsAntioxidant therapyBioactive compoundsGlaucoma managementNeuroprotectionPrecision medicine

Identifiers

PMID40683209
PMCPMC12401487

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.